Cargando…

The Value of LncRNA BCAR4 as a Prognostic Biomarker on Clinical Outcomes in Human Cancers

Background: This updated meta-analysis aimed to analyze available data to explore the prognostic value of long noncoding RNA breast cancer anti-estrogen resistance 4 (BCAR4) in various human malignancies. Methods: Literature retrieval was performed by systematic searching several authoritative datab...

Descripción completa

Detalles Bibliográficos
Autores principales: Tu, Chao, Ren, Xiaolei, He, Jieyu, Zhang, Chenghao, Chen, Ruiqi, Wang, Wanchun, Li, Zhihong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6856575/
https://www.ncbi.nlm.nih.gov/pubmed/31762809
http://dx.doi.org/10.7150/jca.35113
_version_ 1783470595930849280
author Tu, Chao
Ren, Xiaolei
He, Jieyu
Zhang, Chenghao
Chen, Ruiqi
Wang, Wanchun
Li, Zhihong
author_facet Tu, Chao
Ren, Xiaolei
He, Jieyu
Zhang, Chenghao
Chen, Ruiqi
Wang, Wanchun
Li, Zhihong
author_sort Tu, Chao
collection PubMed
description Background: This updated meta-analysis aimed to analyze available data to explore the prognostic value of long noncoding RNA breast cancer anti-estrogen resistance 4 (BCAR4) in various human malignancies. Methods: Literature retrieval was performed by systematic searching several authoritative databases, including Pubmed, PMC database, Web of Science, the Cochrane Library, Embase, and CNKI database up to Feb 10, 2019. Data were extracted and subsequently crosschecked, and discrepancies were discussed to reach consensus. Quality of the eligible studies was evaluated by Newcastle-Ottawa Scale (NOS). The fixed- or random-effects model was used to calculate the pooled the hazard ratios (HRs) or odds ratios (ORs) and the 95% confidence interval (95% CI). Publication bias was detected by using Begg's funnel plot and Egger's test. Results: A total 1,128 cancer patients from thirteen studies were included and pooled in the present meta-analysis. High expression levels of BCAR4 were correlated with unfavorable overall survival (OS) (HR=2.23, 95% CI: 1.84-2.71), but not progression-free survival (PFS) (HR=1.30, 95% CI: 0.80-2.11). Subgroup stratified analysis showed that tumor type, sample size, follow-up months, and survival analysis method did not alter the predictive value of BCAR4 on OS in various cancers. Furthermore, elevated BCAR4 level was markedly correlated with advanced clinical stage (III/IV) (OR=3.28, 95% CI: 2.33-4.60), and dramatically predicted lymph node metastasis (OR=3.00, 95% CI: 1.95-4.63, P<0.00001) and distant metastasis (OR=3.36, 95% CI: 1.88-5.98, P<0.0001), but not associated with age, gender or tumor size. No obvious heterogeneity was noted for correlation between BCAR4 expression and OS across these studies. Conclusions: High expression of BCAR4 was correlated with unfavorable overall survival outcome and clinical features including metastasis and progression, implicating an independent prognostic value for BCAR4 in human cancers.
format Online
Article
Text
id pubmed-6856575
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-68565752019-11-24 The Value of LncRNA BCAR4 as a Prognostic Biomarker on Clinical Outcomes in Human Cancers Tu, Chao Ren, Xiaolei He, Jieyu Zhang, Chenghao Chen, Ruiqi Wang, Wanchun Li, Zhihong J Cancer Research Paper Background: This updated meta-analysis aimed to analyze available data to explore the prognostic value of long noncoding RNA breast cancer anti-estrogen resistance 4 (BCAR4) in various human malignancies. Methods: Literature retrieval was performed by systematic searching several authoritative databases, including Pubmed, PMC database, Web of Science, the Cochrane Library, Embase, and CNKI database up to Feb 10, 2019. Data were extracted and subsequently crosschecked, and discrepancies were discussed to reach consensus. Quality of the eligible studies was evaluated by Newcastle-Ottawa Scale (NOS). The fixed- or random-effects model was used to calculate the pooled the hazard ratios (HRs) or odds ratios (ORs) and the 95% confidence interval (95% CI). Publication bias was detected by using Begg's funnel plot and Egger's test. Results: A total 1,128 cancer patients from thirteen studies were included and pooled in the present meta-analysis. High expression levels of BCAR4 were correlated with unfavorable overall survival (OS) (HR=2.23, 95% CI: 1.84-2.71), but not progression-free survival (PFS) (HR=1.30, 95% CI: 0.80-2.11). Subgroup stratified analysis showed that tumor type, sample size, follow-up months, and survival analysis method did not alter the predictive value of BCAR4 on OS in various cancers. Furthermore, elevated BCAR4 level was markedly correlated with advanced clinical stage (III/IV) (OR=3.28, 95% CI: 2.33-4.60), and dramatically predicted lymph node metastasis (OR=3.00, 95% CI: 1.95-4.63, P<0.00001) and distant metastasis (OR=3.36, 95% CI: 1.88-5.98, P<0.0001), but not associated with age, gender or tumor size. No obvious heterogeneity was noted for correlation between BCAR4 expression and OS across these studies. Conclusions: High expression of BCAR4 was correlated with unfavorable overall survival outcome and clinical features including metastasis and progression, implicating an independent prognostic value for BCAR4 in human cancers. Ivyspring International Publisher 2019-10-15 /pmc/articles/PMC6856575/ /pubmed/31762809 http://dx.doi.org/10.7150/jca.35113 Text en © The author(s) This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
spellingShingle Research Paper
Tu, Chao
Ren, Xiaolei
He, Jieyu
Zhang, Chenghao
Chen, Ruiqi
Wang, Wanchun
Li, Zhihong
The Value of LncRNA BCAR4 as a Prognostic Biomarker on Clinical Outcomes in Human Cancers
title The Value of LncRNA BCAR4 as a Prognostic Biomarker on Clinical Outcomes in Human Cancers
title_full The Value of LncRNA BCAR4 as a Prognostic Biomarker on Clinical Outcomes in Human Cancers
title_fullStr The Value of LncRNA BCAR4 as a Prognostic Biomarker on Clinical Outcomes in Human Cancers
title_full_unstemmed The Value of LncRNA BCAR4 as a Prognostic Biomarker on Clinical Outcomes in Human Cancers
title_short The Value of LncRNA BCAR4 as a Prognostic Biomarker on Clinical Outcomes in Human Cancers
title_sort value of lncrna bcar4 as a prognostic biomarker on clinical outcomes in human cancers
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6856575/
https://www.ncbi.nlm.nih.gov/pubmed/31762809
http://dx.doi.org/10.7150/jca.35113
work_keys_str_mv AT tuchao thevalueoflncrnabcar4asaprognosticbiomarkeronclinicaloutcomesinhumancancers
AT renxiaolei thevalueoflncrnabcar4asaprognosticbiomarkeronclinicaloutcomesinhumancancers
AT hejieyu thevalueoflncrnabcar4asaprognosticbiomarkeronclinicaloutcomesinhumancancers
AT zhangchenghao thevalueoflncrnabcar4asaprognosticbiomarkeronclinicaloutcomesinhumancancers
AT chenruiqi thevalueoflncrnabcar4asaprognosticbiomarkeronclinicaloutcomesinhumancancers
AT wangwanchun thevalueoflncrnabcar4asaprognosticbiomarkeronclinicaloutcomesinhumancancers
AT lizhihong thevalueoflncrnabcar4asaprognosticbiomarkeronclinicaloutcomesinhumancancers
AT tuchao valueoflncrnabcar4asaprognosticbiomarkeronclinicaloutcomesinhumancancers
AT renxiaolei valueoflncrnabcar4asaprognosticbiomarkeronclinicaloutcomesinhumancancers
AT hejieyu valueoflncrnabcar4asaprognosticbiomarkeronclinicaloutcomesinhumancancers
AT zhangchenghao valueoflncrnabcar4asaprognosticbiomarkeronclinicaloutcomesinhumancancers
AT chenruiqi valueoflncrnabcar4asaprognosticbiomarkeronclinicaloutcomesinhumancancers
AT wangwanchun valueoflncrnabcar4asaprognosticbiomarkeronclinicaloutcomesinhumancancers
AT lizhihong valueoflncrnabcar4asaprognosticbiomarkeronclinicaloutcomesinhumancancers